P
Peter G. Gibson
Researcher at University of Newcastle
Publications - 774
Citations - 53254
Peter G. Gibson is an academic researcher from University of Newcastle. The author has contributed to research in topics: Asthma & Sputum. The author has an hindex of 103, co-authored 711 publications receiving 45722 citations. Previous affiliations of Peter G. Gibson include University of Sydney & National Health and Medical Research Council.
Papers
More filters
Journal ArticleDOI
Chlamydial Respiratory Infection during Allergen Sensitization Drives Neutrophilic Allergic Airways Disease
Jay C. Horvat,Malcolm R. Starkey,Richard Kim,Kenneth W. Beagley,Kenneth W. Beagley,Julie A. Preston,Peter G. Gibson,Paul S. Foster,Philip M. Hansbro +8 more
TL;DR: Inhibition of pulmonary neutrophil influx during infection blocked OVA-induced neutrophilic inflammation and T cell IFN-γ production and reversed the suppressive effects on mucus-secreting cell hyperplasia and AHR during AAD.
Journal ArticleDOI
Long-acting beta2-agonists versus theophylline for maintenance treatment of asthma.
TL;DR: Long-acting beta-2 agonists, particularly salmeterol, are more effective than theophylline in improving morning and evening PEF, but are not significantly different in their effect on FEV1.
Journal ArticleDOI
Monitoring the patient with asthma: an evidence-based approach.
TL;DR: The monitoring of symptoms, airflow obstruction, and exacerbations is essential to asthma management and regular monitoring by physicians improves health outcomes for patients, provided the physician is systematic and monitors control, medications, and skills at regular intervals.
Journal ArticleDOI
Streptococcus pneumoniae infection suppresses allergic airways disease by inducing regulatory T-cells
Julie A. Preston,Alison N. Thorburn,Malcolm R. Starkey,Emma L. Beckett,Jay C. Horvat,Margaret A. Wade,Brendan O'Sullivan,Ranjeny Thomas,Kenneth W. Beagley,Peter G. Gibson,Paul S. Foster,Phillip M. Hansbro +11 more
TL;DR: The potential for the development of therapeutic agents for asthma from S. pneumoniae attenuates allergic immune responses and suppresses AAD, and these effects may be mediated by S pneumoniae-induced Tregs.
Journal ArticleDOI
Chlamydia pneumoniae immunoglobulin A reactivation and airway inflammation in acute asthma
TL;DR: Serological features suggest that Chlamydia pneumoniae reactivation may trigger neutrophilic airway inflammation in acute asthma, and an acute antibody response to C. pneumoniae is common in exacerbations of asthma.